作者：财富情报局水寒 12月20日，以"破局·重构"为主题的雪球嘉年华在上海举行，神农投资总经理陈宇结合自己的投资策略 对2026年A股市场机会点进行了展望。 陈宇透露，今年其投资策略主要聚焦于创新药和Ai领域。关于创新药，陈宇在2024年就曾表达过看好观 点。当时他认为，2025年的创新药行业就相当于2005年的房地产行业。借鉴美日两国医药指数市场表 现，长远来看都很可观。 但同时，由于创新药赛道的特殊性，陈宇也建议二级市场投资者慎入，主要原因在于，创新药赛道是九 死一生的生意，再好的公司也可能因为一款创新药的研发失败而被替代，导致该赛道胜率低、赔率高。 除了创新药板块，另一个被陈宇大为看好的行业则是Ai应用领域。陈宇认为，2026年的Ai应用行业就相 当于2006年的房地产行业，将迎来集中爆发期。虽然当下Ai产业投资异常火热，但这几年资金主要集中 于算力和硬件等领域，明年无论是A股还是港股，Ai应用领域的投资都将孕育巨大机会。 此外，陈宇也对美联储降息及投资者颇为关切的量化发展等问题表达了自己的看法。 • 美联储降息影响。陈宇认为，宏观环境下，加息降息本质是钱多钱少的问题，市场结构分化下，对核 心产业如A ...

Investment Rating - The report maintains a "Recommended" rating for the industry [7] Core Insights - The report highlights the potential of in vivo CAR-T therapies to address accessibility issues in CAR-T treatments, which are currently expensive and limited in availability [12][15] - It emphasizes the strategic positioning of multinational corporations (MNCs) in the in vivo CAR-T space, with significant business development (BD) transactions exceeding $5 billion [17] - The report identifies three key investment directions for 2026: BD 2.0, small nucleic acids, and supply chain innovations [3] Summary by Sections In Vivo CAR-T Developments - In vivo CAR-T therapies are expected to lower treatment costs and improve patient accessibility, potentially transforming cancer treatment [12][15] - Major pharmaceutical companies are actively acquiring in vivo CAR-T technologies, indicating a strong market interest [17] - Clinical data from various studies show promising efficacy for in vivo CAR-T therapies, with high response rates in difficult-to-treat patient populations [19] Market Review and Analysis - The pharmaceutical and biotechnology index experienced a slight decline of 0.14% during the week of December 15-19, 2025, outperforming both the ChiNext and CSI 300 indices [25] - The report notes that the pharmaceutical sector's trading volume was 389.82 billion yuan, accounting for 4.49% of the total market, which is below the historical average of 7.12% [45] - The report suggests that despite recent underperformance, many stocks are entering a value range, indicating potential for recovery [2] Investment Recommendations - The report recommends focusing on companies that are leading in the in vivo CAR-T space, such as King’s Ray, Shiyao Group, Anke Bio, and others [24][23] - It suggests that investors should pay attention to the ongoing developments in CXO, AI innovative drugs, and small nucleic acids as key areas for potential gains [3]

以下文章来源于e公司 ，作者证券时报 聂英好 周内涨幅最高的机构调研个股为震有科技，本周涨21.89%，航天智造、经纬恒润-W、南京商旅、红棉股份等9家公司涨幅超过10%，其中红棉股份、雪 人集团、德联集团周内实现首板。 热门标的方面，本周有长安汽车、一品红、博盈特焊、华通线缆等4家公司接受百家以上机构调研，其中长安汽车迎来最多机构投资者， 博盈特焊则在一 周之内接待4次机构调研。 长安汽车获得首批L3准入 长安汽车（000625）本周接受214家机构调研，因工信部在12月15日宣布，发放我国首批L3级有条件自动驾驶车型产品准入许可。 极狐汽车与长安汽车 的两款纯电动轿车获得资质，将在北京、重庆指定区域开展上路试点，长安汽车获批车型为旗下深蓝SL03。 e公司 . e公司，证券时报旗下专注上市公司新媒体产品，立志打造A股上市公司资讯第一平台。提供7x24小时上市公司标准化快讯，针对可能影响上市公司股价的 主题概念、行业事件及时采访二次解读，从投资者需求出发，直播上市公司有价值的活动、会议。 来源：e公司 本周（12月15日—12月19日）共有165家上市公司披露机构调研记录，从赚钱效应看，机构调研股涨跌各半， ...

Core Insights - The Chinese biopharmaceutical industry has significantly improved in both the quantity and quality of innovative drugs, with 43 innovative drugs approved in the first half of 2025, a 59% year-on-year increase, and domestic innovative drugs accounting for 93% of this total [1][7] - The industry has evolved from a focus on generic drugs to a strong emphasis on original innovation, supported by policy reforms and increased R&D investment [5][7] - The geopolitical landscape poses challenges for the industry, necessitating a strategic global positioning and market diversification to mitigate risks associated with supply chain security and international cooperation barriers [2][3] Industry Development - The transformation of the Chinese biopharmaceutical industry began with the 2015 reform of the drug approval system, which shifted the focus to clinical value and significantly shortened approval times [5] - The industry has seen a shift from a model of "combination of imitation and innovation" to "source innovation," with substantial increases in R&D investment over the past decade [5][6] - The successful case of the drug Senglitin, which bypassed phase II clinical trials due to its strong performance in phase I trials, exemplifies the supportive environment for innovation in China [6] Global Positioning - The Chinese biopharmaceutical industry is increasingly targeting emerging markets in Southeast Asia and the Middle East, facilitated by regulatory cooperation under the Belt and Road Initiative [2][3] - The industry is forming a diversified international cooperation model, addressing local healthcare needs while enhancing resilience against geopolitical risks [3] Capital Market Dynamics - The capital market for biopharmaceuticals has experienced volatility, with a significant contraction in financing since 2022, but signs of recovery are emerging as of mid-2025 [8][9] - The need for "patient capital" is emphasized, with suggestions to relax investment restrictions for long-term capital sources to strengthen the ecosystem [9][10] - A proposed mechanism linking IPO approvals to the outcomes of major national drug projects aims to enhance funding opportunities for innovative companies [10] Technological Advancements - The application of artificial intelligence (AI) in drug development is becoming a key driver for innovation, improving efficiency in clinical trials and enhancing drug accessibility [11][12] - AI's role in integrating data across various stakeholders is crucial for establishing reasonable pricing and ensuring the sustainability of innovative drugs [12] Future Outlook - The transition from a "China New" to a "Global New" paradigm requires ongoing collaboration among policymakers, industry leaders, researchers, and capital markets, focusing on clinical value and global perspectives [13]

Market Overview - The Hong Kong stock market has experienced continuous fluctuations and adjustments over the past month, with the Hang Seng Index declining by 2.63%, approximately 700 points, and the Hang Seng China Enterprises Index falling by 4.58%, over 400 points [1] - The Hang Seng Technology Index has also decreased by 4.83%, nearly 300 points, with notable declines in tech stocks such as NIO (-17%), Hua Hong Semiconductor (-15%), SMIC (-12%), and Li Auto (-10%) [1] Fundraising and Investment Trends - Since early October, 15 new thematic funds in Hong Kong have chosen to end their fundraising early, particularly technology-themed ETFs, which have rapidly increased their stock positions after establishment, indicating a "fast launch, fast build" characteristic [3] - This trend reflects institutional investors' consensus on the undervaluation of Hong Kong stocks and their proactive approach to seizing the market correction as a buying opportunity [3] Reasons for Market Adjustment - The market adjustment since early October is attributed to a combination of internal and external factors, with the Hang Seng Index dropping 5.85% and the Hang Seng Technology Index experiencing a deeper decline of 18.01% from October 3 to December 19 [5] - Key factors include: 1. Volatility in liquidity expectations due to hawkish statements from Federal Reserve officials, which have weakened interest rate cut expectations and affected global capital flows and valuations in the Hong Kong tech sector [5] 2. Concerns over the "AI bubble" in the U.S. impacting sentiment in the Hong Kong tech sector [5] 3. Increased pressure on the funding environment, with over HKD 1 billion raised from IPOs since new regulations were introduced, significantly impacting market liquidity [5] 4. Profit-taking from previously high-performing tech and consumer stocks, combined with external chip supply news affecting market sentiment [6] Long-term Outlook - Despite short-term pressures, institutions maintain an optimistic long-term outlook for the Hong Kong stock market, predicting a "slow bull" market in 2026 with attractive valuation ratios and improved liquidity as southbound and overseas capital returns [7] - Key investment themes for 2026 include technology and high-end manufacturing, with a focus on areas such as computing power, semiconductors, consumer electronics, and humanoid robots [7] - High dividend yield assets are also favored in a low-interest-rate environment, with institutions highlighting the stability of dividend-paying stocks [7] - Additionally, the innovative drug and biotechnology sectors are seen as having significant investment opportunities, driven by industry acceleration and favorable policy adjustments [8]

Investment Rating - The report maintains a positive outlook on the insomnia treatment market, highlighting the potential for new drug sales performance in this sector [20][32]. Core Insights - The insomnia treatment market in China is characterized by a significant unmet need, with over 200 million individuals estimated to suffer from insomnia symptoms, representing a large consumer market potential [16][24]. - The report emphasizes the shift towards innovative insomnia medications, particularly focusing on new types of benzodiazepine receptor agonists (BZRAs) and dual orexin receptor antagonists (DORAs) as key areas for development [25][38]. - The introduction of new drugs like JY-202 (地达西尼) and DORA medications is expected to reshape the market dynamics, with a forecasted rapid increase in market share and sales [34][39]. Market Overview - The insomnia drug market in China has seen stagnant growth due to a lack of new effective treatments, with the market size in 2023 estimated at 31.62 billion yuan [24]. - The report outlines the historical sales performance of major insomnia medications, indicating a long gap since the last new product launch in 2007, which has contributed to the current market stagnation [24][25]. - The report projects a significant increase in the market size and sales for innovative insomnia drugs, particularly with the anticipated approval and market entry of new products [34][39]. Drug Development Trends - The report identifies two main directions for insomnia drug innovation: improvements on existing BZRAs and the development of DORAs, which are expected to have lower addiction risks and better patient compliance [25][38]. - The new drug JY-202 is highlighted for its selective action on the GABAA receptor, which may reduce side effects associated with traditional insomnia medications [34]. - The report also notes the successful clinical trial results for DORAs, which have shown significant improvements in sleep quality without the risk of addiction, making them suitable for broader consumer use [38][39]. Key Players and Recommendations - The report suggests focusing on companies like 京新药业 (JY-202) and 先声药业 (DORA medications) as they are positioned to capitalize on the emerging market opportunities in insomnia treatment [34][39]. - It recommends monitoring the sales performance of these new drugs as they enter the market, particularly in the context of changing consumer behavior and increasing awareness of sleep health [20][32].

Investment Rating - The report suggests a positive investment outlook for the innovative drug sector and anticipates a reversal of challenges in the left-side sectors, identifying them as the biggest investment opportunities in the pharmaceutical sector for 2025 [4]. Core Insights - The launch of the Ant Group's AI health application "Antifufu" has significantly increased attention on the medical AI theme, addressing previous issues in internet healthcare such as low user engagement and limited access to quality medical resources [1][12]. - Takeda's TYK2 inhibitor Zasocitinib has successfully met all primary and secondary endpoints in its Phase III clinical trials for moderate to severe plaque psoriasis, with over 50% of patients achieving PASI 90 and approximately 30% achieving PASI 100 by week 16 [2][44]. - The report highlights the successful results of Eli Lilly's orforglipron in maintaining weight loss over 52 weeks, indicating its potential to extend the usage cycle of GLP-1 medications [2][46]. Summary by Sections AI Medical Applications - The Antifufu app has upgraded its features to include health companionship, health Q&A, and health services, effectively increasing user engagement and linking patients with medications and services [1][12]. - The platform connects with 5,000 hospitals and 300,000 real doctors, democratizing access to quality medical resources [1][12]. Pharmaceutical Sector - Takeda's Zasocitinib has shown promising results in clinical trials, with plans to submit a new drug application to the FDA and other regulatory bodies by the 2026 fiscal year [2][44]. - The report emphasizes the potential of innovative drugs, particularly dual/multi-antibody drugs and those addressing unmet clinical needs in chronic diseases, as key investment opportunities [4]. Biologics - Eli Lilly's orforglipron has demonstrated superior weight maintenance compared to placebo, suggesting a promising future for GLP-1 drugs [2][46][48]. Medical Devices - The domestic continuous glucose monitoring (CGM) market is expected to expand, driven by rapid product iterations and improvements in quality and patient acceptance [3]. Retail Pharmacy - The report notes that leading companies in the pharmacy sector are likely to increase market share through mergers and acquisitions during the industry consolidation phase [3]. Medical Services and Consumer Healthcare - The AI medical market is being validated as a scalable business model, with ongoing developments in AI healthcare applications [3][4]. Key Investment Targets - The report identifies several key companies for investment consideration, including Innovent Biologics, Kintor Pharmaceutical, and others in the pharmaceutical and healthcare sectors [5].

Core Viewpoint - The article emphasizes the significant market potential for insomnia treatment, highlighting the promising sales performance of newly listed drugs in this sector [16][22][24]. Market Overview - The current insomnia medication market in China is estimated at 31.62 billion yuan, with a large unmet demand due to existing medications failing to meet treatment needs [26]. - The proportion of individuals experiencing insomnia symptoms in China is reported at 16.8%, indicating a potential patient population exceeding 200 million [20][31]. Drug Development and Innovation - The development of insomnia medications has evolved through four generations, with the latest focusing on physiological regulation rather than merely sedative effects [21][32]. - New insomnia drugs, particularly novel benzodiazepine receptor agonists (BZRAs) and dual orexin receptor antagonists (DORAs), are gaining traction, with several products recently launched [24][34]. Specific Drug Insights - The newly launched drug, Dazadiline, is expected to capture a significant market share due to its unique mechanism of action and favorable safety profile, with projected peak sales of 15.6 billion yuan [33]. - Dazadiline's pricing is set at 13.88 yuan per day, making it competitive in the market [33]. - DORAs, such as Daridorexant, are noted for their non-addictive properties and potential for broader consumer acceptance, as they do not fall under strict regulatory controls [38]. Market Dynamics - The article discusses the competitive landscape, noting that the introduction of new insomnia treatments could disrupt the existing market dominated by older, less effective medications [26][27]. - The sales performance of insomnia drugs is expected to improve significantly as new products enter the market and address the needs of a large patient population [16][24]. Future Projections - The article forecasts a steady increase in the number of patients treated for insomnia, with the treatment rate projected to rise from 7.5% in 2024 to 12.1% by 2033 [31]. - The market for insomnia medications is anticipated to grow rapidly, driven by the introduction of innovative therapies and an increasing awareness of sleep health [16][24].

Core Insights - A trend of "counter-market buying" is emerging in the Hong Kong stock market amidst ongoing fluctuations, with institutional investors recognizing the valuation opportunities presented by the market correction [1][4]. Group 1: Fundraising and Investment Trends - Since October 10, at least 15 new Hong Kong-themed funds have announced early fundraising closures, covering various types including passive index funds and equity mixed funds [2][3]. - The early closure of fundraising is characterized by significant time reductions, with some funds shortening their fundraising periods by over a month [3]. - Newly launched ETFs have established high stock positions quickly, indicating a strong bullish sentiment, with some ETFs reaching stock positions of 69.53% and 63.32% before listing [3]. Group 2: Institutional Perspectives - Institutions view the current market adjustment as a prime opportunity for building positions, with many believing that the fundamental performance of key stocks remains strong despite recent price declines [4][5]. - The consensus among institutions is that the current valuation levels, with the Hang Seng Index trading at approximately 12 times earnings, represent a significant undervaluation [5]. Group 3: Market Dynamics and Challenges - The Hang Seng Index has seen a cumulative decline of 5.85% and the Hang Seng Tech Index has dropped 18.01% since early October, attributed to various internal and external factors [7]. - Key challenges include fluctuations in liquidity expectations, concerns over the U.S. "AI bubble," and increased pressure from IPO activities, which have raised over 100 billion HKD since new regulations were introduced [7][8]. Group 4: Long-term Outlook and Investment Opportunities - Despite short-term pressures, institutions maintain an optimistic long-term outlook for the Hong Kong market, predicting a "slow bull" market in 2026 driven by improved liquidity and returning capital [9]. - Key investment themes for 2026 include technology and high-end manufacturing, with a focus on sectors such as computing power, semiconductors, and consumer electronics [9][10]. - High dividend yield assets are also favored, with institutions highlighting the stability of dividend-paying stocks in a low-interest-rate environment [9][10].

Group 1 - The core viewpoint of the article highlights a general increase in the pharmaceutical outsourcing sector, with notable stock price rises for companies such as WuXi Biologics (6.11%), Kelun Pharmaceutical (5.52%), and others [1] - According to a report from Century Securities, the recent NDAA legislation has led to a reduction in geopolitical risks, positively impacting the industry [1] - In the first three quarters, the total amount of license-out agreements for innovative drugs in China reached a historical high, indicating a continuous improvement in the innovation drug sector [1] Group 2 - The CXO sector is experiencing a recovery in performance and new orders, with market attention shifting towards preclinical safety evaluation assets [1] - The CXO industry, as an upstream segment of the innovative drug supply chain, is expected to benefit from the enhanced competitiveness of domestic innovative drugs, leading to a rebound in industry prosperity [1] - The outlook for CXO is positive, with expectations for both performance and valuation recovery following a complete industry cycle [1]